Calibration of human coagulation factor VII concentrate Ph. Eur. BRP batch 2.

Q4 Medicine Pharmeuropa bio & scientific notes Pub Date : 2010-04-01
J Dodt, A Costanzo, A Daas, A Hunfeld, K-H Buchheit
{"title":"Calibration of human coagulation factor VII concentrate Ph. Eur. BRP batch 2.","authors":"J Dodt,&nbsp;A Costanzo,&nbsp;A Daas,&nbsp;A Hunfeld,&nbsp;K-H Buchheit","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The potency assay of human coagulation factor VII concentrate preparations as described in the European Pharmacopoeia (Ph. Eur.) requires a reference preparation calibrated in International Units (IU). The current Ph. Eur. Biological Reference Preparation (BRP) batch 1 was established in 2005 during an international collaborative study. It has an assigned potency of 8.2 IU/vial for the chromogenic assay method. Stocks of this BRP are dwindling and a replacement batch needs to be established. A candidate material was produced by a manufacturer from a plasma-derived concentrate preparation, with the same formulation and approximately the same potency, in the interest of continuity. The candidate material fulfilled the requirements of a BRP with regard to precision and homogeneity of fill, residual water content and stability. The potency of the candidate BRP (cBRP) was determined using chromogenic assays as required by the Ph. Eur. and in-house clotting assays in an attempt to assign a potency for both methods, as is the case for the current batch. The statistical model used for most laboratories was the maximum likelihood of the parallel line model using a logarithmic transformation of the responses. In the chromogenic assay, a potency of 9.9 IU/vial (+/- 1.8 %) was obtained for the cBRP with a very good consistency between laboratories. The results from the clotting assay, however, were less homogenous and yielded consistently higher results (13 IU/vial +/- 12 %), probably due to a higher activated factor VII (FVIIa) content than in the current BRP (3 % as compared to 0.3 %). Due to the large difference between the values obtained with the 2 different methods, it was not possible to reconcile the outcomes with each other. On the other hand, the uncertainty observed with the clotting assay method was quite large and seemed questionable for a reference preparation. Therefore the use of BRP batch 2 as a reference for the clotting assay method is not recommended. Nevertheless, the results of the study showed that the candidate BRP (cBRP) is suitable as a reference standard for the chromogenic assay according to the Ph. Eur. general chapter 2.7.10 Assay of human coagulation factor VII. It was adopted by the Ph. Eur. Commission in December 2009 as an official Ph. Eur. BRP for human coagulation factor VII concentrate with an assigned potency of 9.9 IU/vial.</p>","PeriodicalId":39192,"journal":{"name":"Pharmeuropa bio & scientific notes","volume":"2010 1","pages":"31-8"},"PeriodicalIF":0.0000,"publicationDate":"2010-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmeuropa bio & scientific notes","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The potency assay of human coagulation factor VII concentrate preparations as described in the European Pharmacopoeia (Ph. Eur.) requires a reference preparation calibrated in International Units (IU). The current Ph. Eur. Biological Reference Preparation (BRP) batch 1 was established in 2005 during an international collaborative study. It has an assigned potency of 8.2 IU/vial for the chromogenic assay method. Stocks of this BRP are dwindling and a replacement batch needs to be established. A candidate material was produced by a manufacturer from a plasma-derived concentrate preparation, with the same formulation and approximately the same potency, in the interest of continuity. The candidate material fulfilled the requirements of a BRP with regard to precision and homogeneity of fill, residual water content and stability. The potency of the candidate BRP (cBRP) was determined using chromogenic assays as required by the Ph. Eur. and in-house clotting assays in an attempt to assign a potency for both methods, as is the case for the current batch. The statistical model used for most laboratories was the maximum likelihood of the parallel line model using a logarithmic transformation of the responses. In the chromogenic assay, a potency of 9.9 IU/vial (+/- 1.8 %) was obtained for the cBRP with a very good consistency between laboratories. The results from the clotting assay, however, were less homogenous and yielded consistently higher results (13 IU/vial +/- 12 %), probably due to a higher activated factor VII (FVIIa) content than in the current BRP (3 % as compared to 0.3 %). Due to the large difference between the values obtained with the 2 different methods, it was not possible to reconcile the outcomes with each other. On the other hand, the uncertainty observed with the clotting assay method was quite large and seemed questionable for a reference preparation. Therefore the use of BRP batch 2 as a reference for the clotting assay method is not recommended. Nevertheless, the results of the study showed that the candidate BRP (cBRP) is suitable as a reference standard for the chromogenic assay according to the Ph. Eur. general chapter 2.7.10 Assay of human coagulation factor VII. It was adopted by the Ph. Eur. Commission in December 2009 as an official Ph. Eur. BRP for human coagulation factor VII concentrate with an assigned potency of 9.9 IU/vial.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人凝血因子VII浓缩液Ph. Eur的校准。BRP批次2。
欧洲药典(Ph. Eur.)中描述的人凝血因子VII浓缩制剂的效价测定需要以国际单位(IU)校准的参考制剂。目前的博士学位。生物参比制剂(BRP)第1批于2005年在一项国际合作研究中建立。显色法的指定效价为8.2 IU/瓶。这种BRP的库存正在减少,需要建立一个替代批次。候选材料由制造商从血浆衍生浓缩制剂中生产,具有相同的配方和大致相同的效力,以保持连续性。候选材料在填充精度和均匀性、残余含水量和稳定性方面满足BRP的要求。候选BRP (cBRP)的效价根据欧洲药典的要求用显色法测定。内部凝血试验试图为两种方法分配效力,就像当前批次的情况一样。大多数实验室使用的统计模型是使用响应的对数变换的平行线模型的最大似然。在显色分析中,cBRP的效价为9.9 IU/瓶(+/- 1.8%),在实验室之间具有很好的一致性。然而,凝血试验的结果不太均匀,结果始终较高(13 IU/瓶+/- 12%),可能是由于激活因子VII (FVIIa)含量高于目前的BRP(3%比0.3%)。由于两种不同方法得到的结果差异较大,因此无法使结果相互协调。另一方面,用凝血测定法观察到的不确定度相当大,似乎值得怀疑作为参考制剂。因此,不建议使用BRP批2作为凝血测定方法的参考。尽管如此,研究结果表明候选BRP (cBRP)适合作为显色试验的参考标准。总论2.7.10人凝血因子VII的测定。它已被欧洲理事会通过。欧盟委员会2009年12月正式授予欧洲博士学位。人凝血因子VII浓缩物的BRP,指定效价为9.9 IU/瓶。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmeuropa bio & scientific notes
Pharmeuropa bio & scientific notes Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
0
期刊最新文献
Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2. Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay. Ph. Eur. testing for histamine and depressor substances using guinea-pigs and cats: the end of an era. Strategy for removal of animal tests for histamine and depressor substances and their vestiges from the Ph. Eur. International collaborative study to assess new stocks of candidate reference preparations to control the level of anti-D in IVIG
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1